Only 10% increase in the Group of Chinese Gods

The recently sought-after group of Chinese deities (000790, closing 14.35 Yuan) released its interim results today (July 27), when the company's operating income reached 201 million yuan, up 9.63% year-on-year, net profit reached 3.9247 million yuan, up 251.49% Earnings per share of 0.0148 yuan, up 260.98% year-on-year, net assets yield 0.86%, up 0.58% from a year earlier.　　But the market attention of the pharmaceutical business performance is not satisfactory, gross margin fell 0.34% year-on-year, which is regarded as a potential product of the single anti-drug business income rose only 10.48% to 8.4037 million yuan, gross margin fell 0.57%. By the national policy and the impact of the market, the pharmaceutical plate in the past one months has become a a-share "hardest hit", the Chinese god Group has become a few of the trend of a gratifying medical unit. The unit has climbed steadily since entering late June, from June 21 to yesterday, with cumulative gains of 43.79% per cent. It can also be seen from the Half-year report that since the middle and late June, the agency has conducted intensive joint research on the company.　　From June 17 to June 25, including Guotai, Huaxia fund, Chinese security and other securities brokerage, funds and insurance four batches to the company site visits. Analysts told the Daily Economic news reporter that the biggest highlight of the group is the "statin" products it has developed in recent years. The company said in public information that the drug is the first in the world to use monoclonal antibodies for radionuclide labeling targeted treatment of liver cancer gene drugs, the effective rate reached 38%.　　Licatin in 2007, operating income and gross profit margin has been growing rapidly. From 2007 to 2009, the business income of this product reached 2.823 million yuan, 10.1743 million yuan and 15.9178 million yuan respectively. Gross margin also rose from 62.25% in 2008 to 66.34%. According to the company's forecast, the next two years gross margin is expected to reach 80%.　　The company also issued a targeted issuance program on June 5, to raise 275 million yuan to invest in the development of a number of other projects. However, the reported figures published today do not seem to match expectations. Licatin only sold 8.4037 million yuan in the first half, a slight increase of 10.48%. Gross margin of 68.4%, down 0.57% year-on-year.　　Licatin, a brokerage analyst, said the price of $28,800 per unit might be a major obstacle to sales. The other two groups of Hua Shen Group of drugs, nasal yuan Shu oral liquid and 37 Tong Shu capsule gross margin also fell 0.81% and 2.3% respectively. Steel production business gross profit margin fell 6.43% year-on-year, steel structure project Rose 3.79%. Overall gross profit rose 6.22% per cent year-on-year, to 32.59%.